April 28, 2026
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 1, 2026
VivoSim Announces Pricing of up to a $4 Million Public Offering
March 24, 2026
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
March 3, 2026
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
February 11, 2026
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
January 29, 2026
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
January 6, 2026
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer